CEO sold ~$46K of Edwards Lifesciences
Scheduled in advanceTraded May 22, 2026 · Filed May 22, 2026
Edwards Lifesciences's CVP, TMTT & Surgical sold $127K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$126,905
Shares × reported transaction price
29 days after results of Apr 23, 2026, 62 days before results of Jul 23, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $85.78 on May 22, 2026, within 2% of its 52-week high, after a 10% rise over the previous 30 trading days
52-week range $72.65 (Oct 16, 2025) to $87.18 (Mar 2, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $77.87 on Apr 10, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.1% | +1.2% | -1.1% |
| 30 days | +2.5% | -2.2% | +4.7% |
| 90 days | +3.4% | +1.7% | +1.7% |
Past results only. Not a forecast.
CEO sold ~$46K of Edwards Lifesciences
Scheduled in advance16K → 15K shares held−4% of their stake
Edwards Lifesciences's SVP, Corporate Controller sold $49K of Edwards Lifesciences shares. Nobody planned it ahead of time.
122K → 99K shares held−19% of their stake
Edwards Lifesciences's CVP,Strategy/Corp Development sold $2M of Edwards Lifesciences shares. Nobody planned it ahead of time.